#Remdesivir of scant benefit in hospitalized #COVID patients, study finds | CIDRAP
▻https://www.cidrap.umn.edu/news-perspective/2020/08/remdesivir-scant-benefit-hospitalized-covid-patients-study-finds
Kaplan-Meier estimates of death from any cause at 28 days of treatment were 1% (95% CI, 0.0% to 2.6%) in the 5-day remdesivir group (log-rank P = 0.43 vs standard care), 2% (95% CI, 0.0% to 3.6%) in the 10-day remdesivir group (log-rank P = 0.72 vs standard care), and 2% (95% CI, 0.1% to 4.1%) in the group receiving standard care.
Adverse events, clinical outcomes
Any differences between the groups receiving remdesivir versus standard care in duration of supplemental oxygen or hospitalization were not significant.